Patients with post-traumatic stress disorder (PTSD) tend to show signs of a relatively increased inflammatory state suggesting that activation of the immune system may contribute to the development of PTSD. In the present study, we tested whether activation of the innate immune system can disrupt acquisition or recall of auditory fear extinction using an animal model of PTSD. Male adolescent rats received auditory fear conditioning in context A. The next day, an intraperitoneal injection of lipopolysaccharide (LPS; 100 lg/kg) prior to auditory fear extinction in context B impaired acquisition and recall of extinction. LPS (100 lg/kg) given after extinction training did not impair extinction recall suggesting that LPS did not affect consolidation of extinction. In contrast to cued fear extinction, contextual fear extinction was not affected by prior injection of LPS (100 lg/kg). Although LPS also reduced locomotion, we could dissociate the effects of LPS on extinction and locomotion by using a lower dose of LPS (50 lg/kg) which impaired locomotion without affecting extinction. In addition, 15 h after an injection of 250 lg/kg LPS in adult rats, extinction learning and recall were impaired without affecting locomotion. A sub-chronic treatment with candesartan, an angiotensin II type 1 receptor blocker, prevented the LPS-induced impairment of extinction in adult rats. Our results demonstrate that activation of the innate immune system can disrupt auditory fear extinction in adolescent and adult animals. These findings also provide direction for clinical studies of novel treatments that modulate the innate immune system for stress-related disorders like PTSD.
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Introduction
Post-traumatic stress disorder (PTSD) is a severe stress disorder that can develop after experiencing significant physical and/or psychological trauma (Jakovljević et al., 2012) . Current treatments for PTSD produce inconsistent results (Asnis et al., 2004; Cohen et al., 2011; Rosen et al., 2013) . Therefore, the search for novel and effective pharmacological treatment is of major interest. Patients with PTSD show lower levels of peripheral cortisol (Bierer et al., 2006) , increased glucocorticoid sensitivity (Rohleder et al., 2004) , and altered diurnal rhythms of cortisol levels (de Kloet et al., 2006; Yehuda et al., 2005) leading to a clinical pattern of low HPA axis activity.
By activating glucocorticoid receptors in immune cells, cortisol modulates gene transcription to decrease inflammation (Adcock et al., 2004) . Since cortisol has anti-inflammatory effects, the reduced cortisol levels in PTSD could lead to a relatively increased inflammatory state in these patients. Consistent with this possibility, previous studies found that patients with PTSD also have increased expression of the pro-inflammatory cytokines IL-1b, IL-6, and TNF-a (Gill et al., 2008; Guo et al., 2012; Lindqvist et al., 2014; Rohleder et al., 2004; Sánchez-Lemus et al., 2009; van Zuiden et al., 2012) . It has been hypothesized that increased inflammatory cytokines are involved in the pathogenesis of PTSD symptoms such as re-experiencing the traumatic event (Jones and Thomsen, 2013) . In support of this hypothesis, the levels of IL-6 and TNF-a positively correlate with the severity of PTSD symptoms (Gola et al., 2013) . However, it is not clear whether an inflammatory state leads to PTSD or whether PTSD causes an inflammatory state.
One possibility is that the inflammatory state contributes to the impaired fear extinction seen in patients with PTSD (Milad et al., 
